Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M9.1Revenue $M15.2Net Margin (%)-98.3Altman Z-Score-4.1
Enterprise Value $M2.6EPS $-0.4Operating Margin %-101.8Piotroski F-Score2
P/E(ttm)--Beneish M-Score-3.3Pre-tax Margin (%)-98.3Higher ROA y-yY
Price/Book0.310-y EBITDA Growth Rate %-11.2Quick Ratio1.2Cash flow > EarningsY
Price/Sales0.65-y EBITDA Growth Rate %4.0Current Ratio1.6Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-27.6Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-39.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M40.7ROIC % (ttm)-49.1Gross Margin Increase y-yN

Gurus Latest Trades with KOOL

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
KOOLKen Fisher 2011-09-30 Sold Out -0.0001%$1.2 - $2.13
($1.73)
$ 0.22-87%Sold Out0
KOOLKen Fisher 2011-06-30 Buy $1.91 - $2.47
($2.2)
$ 0.22-90%New holding20,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

KOOL is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


KOOL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Harris KennethFormer Director/Officer 2015-11-10Sell80,858$0.6-63.33view
Harris KennethFormer Director/Officer 2015-11-03Sell10,510$0.6-63.33view
Harris KennethFormer Director/Officer 2015-10-29Sell8,632$0.6-63.33view
Plavan Matthew TFormer CEO 2015-09-02Sell17,271$0.68-67.65view
Rhein Denis MichaelDirector 2014-12-01Sell0$0-67.65view
ENGLE J MELVILLEChairman & CEO 2011-03-10Buy22,500$2.3-90.43view
ARTILES JORGEVP, Quality/Regulatory Affairs 2010-01-13Buy100$2.44-90.98view
ENGLE J MELVILLECEO 2009-09-25Buy25,000$2.28-90.35view
MCENANY PATRICK JDirector 2009-05-19Buy6,250$2.32-90.52view
ENGLE J MELVILLECEO 2009-05-12Buy25,000$2.2-90view

Quarterly/Annual Reports about KOOL:

News about KOOL:

Articles On GuruFocus.com
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 11 2011 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Nov 04 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) May 07 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 04 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Nov 09 2009 
THERMOGENESIS Corp. (KOOL) CEO J Melville Engle buys 100,000 Shares Sep 28 2009 
THERMOGENESIS Corp. (KOOL) CEO J Melville Engle buys 100,000 Shares May 12 2009 
THERMOGENESIS Corp. Reports Operating Results (10-Q) May 07 2009 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 05 2009 

More From Other Websites
CESCA THERAPEUTICS INC. Files SEC form 8-K, Termination of a Material Definitive Agreement Feb 04 2016
Cell Therapy Industry: The Roads to Commercial Success Feb 03 2016
9:01 am Cesca Therapeutics announces $15 mln strategic investment from Boyalife Group Feb 03 2016
Cesca Announces $15 Million Strategic Investment From Boyalife Group Feb 03 2016
CESCA THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered... Feb 03 2016
Cesca Therapeutics Sponsors First Symposium on Haploidentical Stem Cell Transplantation in India Jan 08 2016
Cesca Therapeutics to Present at Biotech Showcase in San Francisco on January 13, 2016 Jan 07 2016
Cesca Therapeutics Sponsors First Symposium on Haploidentical Stem Cell Transplantation in India Jan 05 2016
Cesca Therapeutics downgraded by Maxim Group Dec 22 2015
CESCA THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in... Dec 16 2015
CESCA THERAPEUTICS INC. Financials Dec 08 2015
CESCA RECEIVES APPROVAL FOR MEDICARE COVERAGE Dec 02 2015
Cesca Therapeutics, Inc. Earnings Q1, 2016 Dec 02 2015
Cesca Therapeutics Up 25%: New Medicare Developments Explain Why Dec 02 2015
Cesca Receives Approval for Medicare Coverage Dec 02 2015
Cesca Therapeutics to Present at 2015 LD Micro Main Event Nov 20 2015
Cesca’s Unique Approach to Regenerative Medicine - a Razor-Razor Blade Business Model Nov 19 2015
CESCA THERAPEUTICS INC. Files SEC form 8-K, Financial Statements and Exhibits Nov 18 2015
A double dose of bad news for local biotech firm Nov 17 2015
CESCA THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 16 2015

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK